Neonc Technologies Holdings (NTHI) Return on Sales (2024 - 2025)
Neonc Technologies Holdings (NTHI) posted quarterly Return on Sales of 15.18% for Q4 2025, down 1412.0% year-over-year from 1.16% in Q4 2024, and down 90.36% quarter-over-quarter from 7.97% in Q3 2025.
Neonc Technologies Holdings (NTHI) Return on Sales (2024 - 2025) Analysis & Trends
Neonc Technologies Holdings (NTHI) has reported Return on Sales for 2 consecutive years, with 15.18% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Sales fell 1412.0% year-over-year to 15.18%; the TTM figure through Dec 2025 stood at 15.18% (down 1426.0% YoY), while the FY2025 annual figure was 20.56%, down 1834.0% from the prior year.
- Return on Sales slipped to 15.18% in Q4 2025 per NTHI's latest filing, from 7.97% in the prior quarter.
- Across five years, Return on Sales topped out at 0.19% in Q2 2024 and bottomed at 15.18% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.00% |
| 10 | Neonc Technologies Holdings | 116.41 Mn | 116.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.18% |
| Sep 30, 2025 | -7.97% |
| Jun 30, 2025 | -7.04% |
| Mar 31, 2025 | -8.04% |
| Dec 31, 2024 | -1.05% |
| Jun 30, 2024 | -0.19% |
| Mar 31, 2024 | -0.68% |